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Background

Hydroxychloroquine (HCQ) is an antimalarial medication that has been tested against
various viral illnesses. The available evidence regarding the role of HCQ in the coronavirus
disease 2019 (COVID-19) remains controversial.
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Methods

This is a comparative retrospective cohort study that aims to evaluate the efficacy and
safety of HCQ in hospitalized patients with COVID-19. The primary outcome was all-cause
in-hospital mortality. Secondary outcomes included ICU admission rate, mechanical ventilation, prolonged length of stay (LOS), QTc prolongation and cardiac arrest.

Results

A cohort of 175 hospitalized patients with COVID-19 were included with a median (interquartile range [IQR]) age of 66 [48–79] years. Of whom, 82 (47%) patients received HCQ.
The overall mortality rate was 34.1%; 95% CI [23.7–44.6] and 16.1%; 95% CI [8.5–23.7] in the
HCQ group vs. the control group, respectively (p = 0.67). A Cox regression analysis was
performed adjusting for age, gender, BMI, SpO2/FiO2 ratio and CXR findings, and demonstrated that the association between HCQ use and the all-cause in-hospital mortality was
not statistically significant (HR = 1.15; 95% CI [0.54–2.48]; p-value = 0.72).
Patients who received HCQ were more likely to be admitted to the intensive care unit,
require mechanical ventilation and have a prolonged LOS compared to those who did not
receive the medication. No statistically significant difference was found in the likelihood of
QTc prolongation or cardiac arrest.

Conclusions

The use of HCQ in patients hospitalized with COVID-19 confers no benefit in patient morbidity or mortality.
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Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a contagious respiratory pathogen that originated in Wuhan, China, in
December 2019. On January 21, 2020, the first
case in the United States was confirmed by the
Centers for Disease Control and Prevention

(CDC).1 The number of new cases and deaths
has continued to exponentially increase all
around the world raising the pressing need for
effective therapeutic options.
Chloroquine (CQ) and Hydroxychloroquine
(HCQ) sulfate are 4-aminoquinoline drugs
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developed over 50 years ago and routinely used
worldwide in management of malaria and various rheumatological diseases. In vitro studies
suggested that these medications have antiviral activity against SARS-CoV-1, the Middle
East respiratory syndrome (MERS), human
and avian influenza and most recently, SARSCoV-2.2,3
In consideration of the rapid spread of the
COVID-19 pandemic and its significant morbidity and mortality, the FDA issued an Emergency
Use Authorization (EUA) between March 28th
and June 15th, 2020, for HCQ in the management of COVID-19. During this period, many
studies have demonstrated conflicting data
about the safety and efficacy of CQ and HCQ
in patients with COVID-19. The use of these
medications remains a matter of great controversy. The purpose of this study is to evaluate
the safety and efficacy of HCQ in patients
hospitalized with COVID-19.

Materials and Methods

This is a single-center retrospective cohort
study of hospitalized patients diagnosed with
COVID-19 from March 2020 to May 2020. Study
approval was sought and obtained from the
Institutional Review Board. Patient confidentiality was maintained at all times in accordance
with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) regulations.
Patients who were ≥ 18 years old and hospitalized for more than 24 hours with at least one
positive polymerase chain reaction (PCR) for
COVID-19 were included in the study. Demographic characteristics and clinical data were
manually extracted from the electronic medical records system. Quick SOFA (qSOFA)
and Charlson Comorbidity Index scores were
calculated as previously described.4,5 Patients
with a body temperature of more than 38°C
on admission were considered to have a fever.
Radiographic findings on chest X-ray (CXR)
were determined to be normal, mild, moderate
or severe by a radiologist.
The primary endpoint was all-cause in-hospital mortality. Secondary outcomes included
intensive care unit (ICU) admission rate, mechanical ventilation, prolonged length of stay
(LOS) (more than seven days), corrected QT
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interval (QTc) prolongation and cardiac arrest.
QTc > 500 millisecond or an increase of QTc >
60 milliseconds from baseline were considered
to be prolonged.

Statistical analysis

We categorized the study participants into two
groups based on HCQ administration during
the hospitalization. Patients who received
the standard of care without the use of HCQ
were included in the control group. Continuous
variables were reported as medians (interquartile ranges [IQR]), while categorical variables
were reported as frequencies and percentages. In the comparative analysis, continuous
and categorical variables were analyzed using
Mann-Whitney U tests and chi-square tests;
respectively.
Kaplan Meier test was utilized to estimate the
crude survival time and the unadjusted statistical difference between groups. A Cox proportional hazards model was conducted for time
to death in both groups to estimate the hazard
ratio after adjusting for the age, gender, body
mass index (BMI) and characteristic variables
with a statistically significant difference between the two study groups.
Bivariate and multivariate logistic regression
analyses were used to investigate the association between HCQ treatment and the secondary outcomes before and after adjusting for
confounding factors. All tests were two-tailed,
and a p-value of < 0.05 was considered statistically significant. Statistical analysis was performed using JMP statistical software version
13 (SAS Institute, Cary, NC) and IBM SPSS
Statistics version 26 (IBM Corp., Armonk, NY,
USA).

Results

The cohort included 175 patients with a median
(interquartile range [IQR]) age of 66 (48–79)
years. Eighty-two of these patients (47%)
received HCQ during the hospitalization period and were included in the HCQ group. Seventy-two patients (88%) of the HCQ group,
received azithromycin in addition to HCQ. The
median [IQR] for the length of treatment with
HCQ was 5 [3–6] days, and the median and
[IQR] for the time of initiation of treatment
was 2 [2–4] days from admission. Patients
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Table 1. Demographics and baseline characteristics of the study population.
Total (n=175)
Demographic characteristics

Hydroxychloroquine (n=82)

No Hydroxychloroquine (n=93)

66 (50-77)

63 (45-80)

0.12

47 (57%)

50 (54%)

0.64

48 (61%)

59 (65%)

African American

14 (18%)

14 (16%)

Other

17 (22%)

17 (19%)

Age
Male gender
Race
Caucasian

P value

0.81

Ethnicity

0.73

Hispanic

22 (28%)

23 (25%)

Non-Hispanic

57 (72%)

68 (75%)

28.3 (24.3-32.7)

27.7 (24.6-31.2)

<0.01*

8 (10%)

3 (3%)

0.07

3 (1-5)

3 (0.5-4)

0.41
0.76

BMI
Smoking
Charlson Comorbidity Index
Myocardial infarction

10 (12%)

10 (11%)

CHF

5 (6%)

7 (8%)

0.71

PVD

3 (4%)

1 (1%)

0.25

Stroke/TIA

5 (8%)

2 (2%)

0.18

Dementia

11 (13%)

16 (17%)

0.78

COPD

2 (2%)

5 (5%)

0.31

CTD

5 (6%)

0 (0%)

0.02*

Peptic ulcer disease

1 (1%)

0 (0%)

0.45

Liver disease

0 (0%)

0 (0%)

0.93

25 (31%)

23 (25%)

0.39

Hemiplegia

0 (0%)

0 (0%)

0.75

CKD

4 (5%)

4 (4%)

0.85

Localized tumor

2 (2%)

7 (7%)

0.27
0.50

Diabetes

Metastatic tumor

6 (7%)

1 (1%)

Leukemia

0 (0%)

1 (0%)

0.75

Lymphoma

0 (0%)

1 (1%)

0.50

AIDS

0 (0%)

0 (0%)

0.75

qSOFA score ≥ 1

23 (28%)

21 (23%)

0.56

Respiratory rate >22

0.02*

15 (19%)

6 (7%)

SBP < 100 mmHg

2 (3%)

5 (6%)

0.31

Altered mental status

7 (9%)

12 (13%)

0.34
<0.01*

SpO2/FiO2 ratio

4.2 (2.9-4.6)

4.6 (4.0-4.7)

Fever >38.0 °C

21 (26%)

14 (16%)

0.09

Abnormal CXR findings

65 (79%)

51 (55%)

0.01*

Mild

37 (64%)

29 (38%)

4 (5%)

12 (16%)

Severe

24 (31%)

10 (13%)

Steroids use

15 (20%)

6 (7%)

0.02*

Azithromycin use

72 (88%)

60 (65%)

<0.01*

Moderate

Variables are reported as frequency and percentages (%) or median and interquartile range (IQR).
Abbreviation: BMI; body mass index, CHF; congestive heart failure, PVD; peripheral vascular disease, TIA; transient ischemic attack, COPD;
chronic obstructive pulmonary disease, CTD; connective tissue disease, CKD; chronic kidney disease, AIDS; acquired immunodeficiency syndrome, SBP; systolic blood pressure, SpO2/FiO2; peripheral blood oxygen saturation/fraction of inspired oxygen, CXR; plain chest radiography.
*P values < 0.05
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who received HCQ were more likely to have a
higher BMI, connective tissue disorders, a lower
peripheral blood oxygen saturation/fraction of
inspired oxygen (SpO2/FiO2) ratio and abnormal CXR findings. (Table 1)

Primary outcome

The overall all-cause in-hospital mortality was
24.6%; 95% CI [18.1–31.0] in the total study
population, 34.1%; 95% CI [23.7–44.6] in the
HCQ and 16.1%; 95% CI [8.5–23.7] in the control
group. In a bivariate analysis, there was not a
statistical significant change in survival rate
over time in the HCQ group compare to the
control group (27.6 days; 95% CI [22.2–33.1] and
25.8 days; 95% CI [20.9–30.7] in the HCQ vs.
the control group, respectively); p = 0.67.
In the adjusted Cox regression model, the association between HCQ use and all-cause in-hospital mortality was not statistically significant
(HR = 1.15; 95% CI [0.54–2.48]; p-value = 0.72).
This model was adjusted for age, gender, BMI,
SpO2/FiO2 ratio and CXR findings. (Figure 1)

Secondary outcomes

Patients who received HCQ were more likely to
have a prolonged LOS with a median [IQR] of
9 [5–19] days, compared to 6 [3–10] days in the
control group (p < 0.01). Additionally, the HCQ
group was more likely to be admitted to the
ICU, require mechanical ventilation or have a

prolonged LOS. No significant association was
observed between HCQ use and the incidence
of QTc prolongation or cardiac arrest. The
increased likelihood of ICU admission, mechanical ventilation and prolonged LOS in the HCQ
group remained statistically significant in the
multivariate analysis after adjusting for age,
gender, BMI, SpO2/FiO2 ratio and CXR findings. (Table 2)

Discussion

The role of HCQ in the management of patients with COVID-19 is controversial. Recent
in-vitro evidence and anecdotal clinical data
have suggested a potential benefit for the use
of HCQ in patients with COVID-19.6-8 However,
the early literature should be interpreted with
caution due to the lack of a control group.
In our comparative study, we adjusted for possible confounders and found no mortality benefit for the use of HCQ in hospitalized patients
with COVID-19 compared to the standard of
care.
Our results support findings from previous
observational studies.9-11 One large, singlecenter, study conducted in hospitalized
patients with COVID-19 found no association
between receiving HCQ and mortality
rate.9 Another multicenter cohort study by
Rosenberg et al. showed no mortality benefit

Table 2. In-hospital clinical outcomes and their difference in between the study groups.
Total (n=175)
Clinical outcomes

Hydroxychloroquine
(n=82)

No Hydroxychloroquine
(n=93)

P valuea

P valueb

ICU admission

34 (41%)

2 (2%)

<0.01*

<0.01*

Mechanical
ventilation

16 (20%)

3 (3%)

<0.01*

0.03*

Prolonged LOS

50 (60%)

36 (39%)

<0.01*

<0.01*

QTc prolongation

16 (29%)

6 (19%)

0.16

0.10

5 (6%)

1 (1%)

0.06

0.32

Cardiac arrest

Outcomes are reported as frequency and percentages.
Chi-square test was performed to estimate the statistical significance in difference between groups.
Unadjusted bivariate analysis. b Multivariate analysis adjusted for age, gender, body mass index, peripheral blood oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio and the severity of radiographic findings on chest X-ray.
a

ICU; intensive care unit, LOS; length of stay, QTc; corrected QT interval.
*P values < 0.05.
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Figure 1. Cox proportional hazards model of in-hospital mortality.
for the use of HCQ.10 A retrospective study by
Magagnoli et al. found a higher risk of death in
patients treated with HCQ compared to those
who did not receive the medication.12

found no association between HCQ use, with
or without azithromycin, and the risk of intubation when compared to those who did not
receive the medication.12

Conversely, a retrospective observational study
conducted at the Henry Ford Health System
observed a statistically significant association
between the use of HCQ, with or without
azithromycin, and a higher survival rate among
hospitalized patients with COVID-19.13 The
majority of the patients who received HCQ
also received corticosteroids with a statistically
significant difference between groups. Thus,
these results should be interpreted with caution in light of the recent evidence showing a
clinical benefit for the use of dexamethasone in
hospitalized patients with COVID-19 in lowering the 28-day mortality rate by 17% with a 95%
CI ranging between 7% and 25%.14

In our study, patients treated with HCQ had a
higher incidence of QTc prolongation, although
the association was not statistically significant.
Similarly, a large multinational registry showed
an increased risk of ventricular arrhythmias in
patients treated with HCQ (6.1% compared to
0.3% in controls) without evidence of an added
clinical benefit.16 The risk of ventricular arrhythmias can be explained by the effect of HCQ on
prolonging the QTc interval, particularly when
co-administered with a macrolide. Two cohort
studies of hospitalized patients with COVID-19
observed an increased likelihood of QTc prolongation in patients treated with HCQ. This risk
was higher in those who additionally received
azithromycin.17,18 Additionally, a randomized controlled trial enrolled 150 patients to either HCQ
or standard of care found an increased likelihood of adverse event in the HCQ group (30%
compared to 9% in the standard care group).19

Our study found that patients in the HCQ
group were more likely to have a prolonged
LOS. Similar trends were noted in a randomized clinical trial of 30 treatment-naïve patients
with COVID-19 in China where Chen et al.
demonstrated that patients who were treated with HCQ had a longer hospital stay than
the control group.15 Our study also noted that
patients in the HCQ group were more likely
to require escalation of care leading to admission to the intensive care unit and mechanical
ventilation. On the contrary, Magagnoli et al.

The available evidence to date against the use
of HCQ in patients with COVID-19 outweighs
the available supportive evidence. Two recent
randomized, double-blinded, placebo-controlled trials demonstrated the lack of efficacy of HCQ when used as prophylaxis or early
therapy against COVID-19.20,21 However, both
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trials lacked a consistent proof of exposure to
SARS-CoV-2.

3.

Limitations

Due to its retrospective and observational
nature, our study methodology prevents drawing a causation relation. Moreover, the lack of
randomization introduces a risk of confounding
bias. Patients treated with HCQ in our cohort
were more likely to be sicker at baseline than
those who did not receive the medication. This
can potentially blunt the estimated effect of
HCQ on the tested clinical outcomes. In an
attempt to control for the aforementioned limitations, an adjusted multivariable regression
was performed.

Conclusion

Our study did not find any mortality benefit
from the use of HCQ in patients hospitalized
with COVID-19. In light of the paucity of evidence in support of the benefits of chloroquine
analogs in the management of COVID-19 and
its potential adverse effects, we recommend
restricting the use of Hydroxychloroquine
to clinical trials until more definitive evidence from ongoing randomized clinical trials
(RCTs) aimed to assess the efficacy of HCQ in
COVID-19 becomes available.
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